Rac1/PAK1 signaling contributes to bone cancer pain by Regulation dendritic spine remodeling in rats
Molecular Pain · 2023
DOI: 10.1177/17448069231161031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pain, 2023. Verfasst von Lingfei Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Province Key Laboratory of Anesthesiology, Jiangsu Province Key Laboratory of Anesthesia and Analgesia Application Technology, NMPA Key Labor…. Hauptthemen laut MEDLINE: Cancer Pain, Bone Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The Natural Science Foundation of Universities of Jiangsu Province, Jiangsu Province Postgraduate Research and Practice Innovation Program, The Qing Lan Project of Jiangsu Province.
Abstract (Originalsprache)
Bone cancer pain (BCP) is severe chronic pain caused by tumor metastasis to the bones, often resulting in significant skeletal remodeling and fractures. Currently, there is no curative treatment. Therefore, insight into the underlying mechanisms could guide the development of mechanism-based therapeutic strategies for BCP. We speculated that Rac1/PAK1 signaling plays a critical role in the development of BCP. Tumor cells implantation (TCI) into the tibial cavity resulted in bone cancer-associated mechanical allodynia. Golgi staining revealed changes in the excitatory synaptic structure of WDR (Wide-dynamic range) neurons in the spinal cord, including increased postsynaptic density (PSD) length and thickness, and width of the cleft. Behavioral and western blotting test revealed that the development and persistence of pain correlated with Rac1/PAK1 signaling activation in primary sensory neurons. Intrathecal injection of NSC23766, a Rac1 inhibitor, reduced the persistence of BCP as well as reversed the remodeling of dendrites. Therefore, we concluded that activation of the Rac1/PAK1 signaling pathway in the spinal cord plays an important role in the development of BCP through remodeling of dendritic spines. Modulation of the Rac1/PAK1 pathway may be a potential strategy for BCP treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Province Key Laboratory of Anesthesiology, Jiangsu Province Key Laboratory of Anesthesia and Analgesia Application Technology, NMPA Key Laboratory for Research and Evaluation of Narcotic and Psychotropic Drugs,…
- Department of Anesthesiology, 505488The Affiliated Hospital of Xuzhou Medical University, Jiangsu, China.
- Department of Anesthesiology, 66506Nanjing Drum Tower Hospital, Jiangsu, China.
- 505488Institute of Xuzhou Medical Science, Jiangsu, China.
ORCID-Profile: Su Liu
Förderung
- The Natural Science Foundation of Universities of Jiangsu Province
- Jiangsu Province Postgraduate Research and Practice Innovation Program
- The Qing Lan Project of Jiangsu Province
- Key R&D Program of Xuzhou
Zitieren
APA
Xu, L., Yang, L., Wu, Y., Wan, X., Tang, X., Xu, Y., Chen, Q., Liu, Y., & Liu, S. (2023). Rac1/PAK1 signaling contributes to bone cancer pain by Regulation dendritic spine remodeling in rats. Molecular Pain. https://doi.org/10.1177/17448069231161031
Vancouver
Xu L, Yang L, Wu Y, Wan X, Tang X, Xu Y, et al. Rac1/PAK1 signaling contributes to bone cancer pain by Regulation dendritic spine remodeling in rats. Molecular Pain. 2023. doi:10.1177/17448069231161031
BibTeX
@article{Xu2023,
author = {Xu, Lingfei and Yang, Long and Wu, Yan and Wan, Xinxin and Tang, Xihui and Xu, Yuqing and Chen, Qingsong and Liu, Yuepeng and Liu, Su},
title = {Rac1/PAK1 signaling contributes to bone cancer pain by Regulation dendritic spine remodeling in rats},
journal = {Molecular Pain},
year = {2023},
doi = {10.1177/17448069231161031}
}
EUVIMED